<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04730609</url>
  </required_header>
  <id_info>
    <org_study_id>20-004712</org_study_id>
    <nct_id>NCT04730609</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine for Intraoperative Shivering in Scheduled Elective Cesarean Delivery</brief_title>
  <official_title>Dexmedetomidine for Treatment of Shivering During Scheduled Elective Cesarean Delivery: Determining the Optimal Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the optimum dose of Dexmedetomidine to stop&#xD;
      shivering in 90% of patients who experience shivering during scheduled elective cesarean&#xD;
      deliveries.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Potential subjects will consist of parturients who present for scheduled elective cesarean&#xD;
      deliveries. Patients will be recruited and consented for the study pre-operatively and if&#xD;
      they display Grade 3 or 4 shivering at the time of delivery then they will be enrolled in the&#xD;
      study. Doses of dexmedetomidine will be selected according to a sequential up-and-down&#xD;
      method, using a biased coin design to find the estimated dose at which 90% of patients would&#xD;
      have desired effect - cessation of shivering within 5 minutes of medication administration.&#xD;
      An anesthesia physician not involved in patient care or assessment will prepare the&#xD;
      dexmedetomidine for intravenous use. Anesthesia will be initiated with spinal anesthesia with&#xD;
      our institution's typical dosing of 1.6 mL 0.75% bupivacaine with dextrose, 15 mcg fentanyl,&#xD;
      and 150 mcg morphine.&#xD;
&#xD;
      Shivering will be graded using a five-point scale as outlined by Crossley and Mahajan.&#xD;
      Members of the anesthesia team caring for women in the study will be educated on the grading&#xD;
      scales.&#xD;
&#xD;
        -  Grade 0: no shivering;&#xD;
&#xD;
        -  Grade 1: one or more of the following: piloerection, peripheral vasoconstriction,&#xD;
           peripheral cyanosis, but without visible muscle activity; Grade 2: visible muscle&#xD;
           activity confined to one muscle group;&#xD;
&#xD;
        -  Grade 3: visible muscle activity in more than one muscle group;&#xD;
&#xD;
        -  Grade 4: gross muscle activity involving the whole body&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Shivering will be graded using a five-point scale as outlined by Crossley and Mahajan</measure>
    <time_frame>5 minutes after administration of the drug</time_frame>
    <description>Cessation of shivering</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal Heart Rate</measure>
    <time_frame>During intraoperative course</time_frame>
    <description>Determination of the effect of varying doses of dexmedetomidine on maternal heart rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Doses of dexmedetomidine</measure>
    <time_frame>During intraoperative course</time_frame>
    <description>Determination of the effect of varying doses of dexmedetomidine on maternal sedation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Shivering</condition>
  <condition>Dose Finding Study</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV administration of Dexmedetomidine, using an Up-Down method utilizing a biased coin design to determine that next patient's dose. Initial dose will be 10mcg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Doses of dexmedetomidine will be selected according to a sequential up-and-down method, using a biased coin design to find the estimated dose at which 90% of patients would have desired effect</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women presenting for planned cesarean delivery.&#xD;
&#xD;
          -  American Society of Anesthesiology Physical Classification Status 2 or 3; without&#xD;
             major medical co-morbidities.&#xD;
&#xD;
          -  Singleton gestation in the 3rd trimester (28-42 weeks gestation).&#xD;
&#xD;
          -  Spinal anesthesia technique Women presenting for planned cesarean delivery.&#xD;
&#xD;
          -  American Society of Anesthesiology Physical Classification Status 2 or 3; without&#xD;
             major medical co-morbidities.&#xD;
&#xD;
          -  Singleton gestation in the 3rd trimester (28-42 weeks gestation).&#xD;
&#xD;
          -  Spinal anesthesia technique.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any contraindication to spinal anesthesia technique.&#xD;
&#xD;
          -  Allergy or intolerance to dexmedetomidine or clonidine.&#xD;
&#xD;
          -  Oral temperature &lt; 36Â° Celsius prior to procedure.&#xD;
&#xD;
          -  Unable to give personal consent.&#xD;
&#xD;
          -  PPROM or concern for infection (e.g., chorioamnionitis).&#xD;
&#xD;
          -  Conversion to General Anesthesia prior to randomization.&#xD;
&#xD;
          -  Sedative medications (e.g., fentanyl, midazolam, ketamine, nitrous oxide) administered&#xD;
             prior to randomization.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans Sviggum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>House Tammy</last_name>
      <phone>507-284-9697</phone>
      <email>house.tamara@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 18, 2021</study_first_submitted>
  <study_first_submitted_qc>January 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Hans P. Sviggum, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Shivering</keyword>
  <keyword>Cesarean Delivery</keyword>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Dosing</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

